DOCSLIB.ORG

Herb and Nutrient-Drug Interaction Table

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Herb and Nutrient-Drug Interaction Table Herb and Nutrient-Drug Interaction Table This table provides an overview of the drugs that have been found to interact with the herbal and nutritional medicines discussed in this book. The table is intended to be used as a quick reference guide only and is not exhaustive. As always, due dili- gence is required on a case-by-case basis when making clinical judgements. If a class of drug is not listed here, there was no known interaction found during litera- ture search at the time of publication. However, for many of the herbal extracts listed in the table, further research is required in order to properly establish (or rule out) evidence for herb-drug interactions. The table is organised by drug class. The level of interaction is indicated using the following key: • SI = Serious interaction • UC = Use caution • OB = Clinical observation needed • BI = Potential benefi cial interaction • CYP = Cytochrome P450 © Springer International Publishing Switzerland 2017 185 D. Camfi eld et al. (eds.), Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders, DOI 10.1007/978-3-319-42307-4 186 Herb and Nutrient-Drug Interaction Table cial interaction cial cial interaction cial cial interaction cial ] 8 cial interaction cial ]. Observe in patients who ]. Observe 1 Possible benefi Benefi Possible benefi Discontinue 2–3 weeks prior to [ surgery Avoid combining with alcohol Avoid [ consume moderate to high amounts of alcohol Medical supervision and monitoring of patient advised Medical supervision and monitoring of patient advised Possible benefi Recommendations ] Avoid concurrent use. 7 ]. 9 ] 6 , 5 ] 4 , 3 ] ] ] 1 1 1 ] 2 not yet demonstrated in clinical trials cacy Known interaction with CYP enzymes [ Known Theoretically based on pharmacological study demonstrated action. In vivo in induced liver effects hepatoprotective damage [ Kava has a synergic effect with CNS effect has a synergic Kava depressants [ Evidence to suggest that NAC promotes the Evidence to suggest that NAC metabolism of alcohol and decreases and heart [ damage to the liver Kava has a synergic effect with CNS effect has a synergic Kava depressants [ Kava has a synergic effect with CNS effect has a synergic Kava depressants [ In vivo studies demonstrated inhibited In vivo morphine tolerance and dependence [ Effi Several studies demonstrating studies demonstrating Several thistle of St Mary’s effect hepatoprotective indicate this herb may reduce hepatic tissue damage related to alcohol consumption [ = additive = additive effect = additive = additive effect = decreased side = decreased side = decreased drug = decreased side = reduced drug = additive = additive effect SI effectiveness BI effects UC BI effects SI UC BI tolerance and dependence BI effects (St. Hypericum perforatum wort) John’s Schisandra chinensis Schisandra somnifera Withania Piper methysticum N-Acetylcysteine N-Acetylcysteine Piper methysticum Herb Potential interaction Evidence Silybum marianum Silybum Piper methysticum Anaesthetics (general) Analgesics Codeine Drug class Morphine Alcohol Herb and Nutrient-Drug Interaction Table 187 ] cance cance (continued) 11 cial interaction cial interaction cial ] ] 8 8 cial interaction as well Possible benefi Possible benefi Observe patient with concurrent Observe interaction is use; however, [ unlikely Observe patient with concurrent Observe for use. Interaction risk is low at doses of standardized extracts [ 240 mg/day or lower Observe patient with concurrent Observe interaction is use; however, [ unlikely Unknown clinical signifi Unknown Benefi being a treatment for paracetamol (typically administered overdose in a hospital setting intravenously in the case of overdose) Avoid concurrent use Avoid ] ] Unknown clinical signifi 8 13 ] 7 ] ] 4 7 , ] 3 3 ] ] ] 12 13 10 Based on pharmacological action, may have Based on pharmacological action, may have against liver effect a hepatoprotective damage from paracetamol [ NAC is a proven antidote for is a proven NAC in a as reviewed acetaminophen overdose, 2540 patients. Most protective study of over within 8 h of is taken when NAC paracetamol ingestion [ In vitro seizure models demonstrated [ activity anticonvulsant Demonstrated anticonvulsant activity [ activity Demonstrated anticonvulsant Known interaction with CYP enzymes Known drug metabolism. May cause effecting [ decreased drug effectiveness Based on pharmacological action, may have Based on pharmacological action, may have against liver effect a hepatoprotective damage from paracetamol [ Induction of CYP enzymes, with potentially it has increased drug metabolism; however, not been reported in clinical studies [ One case report of fatal seizure. Possible One case report of fatal acid and interaction with valproic [ reducing drug effectiveness phenytoin, Induction of CYP enzymes, with potential it has increased drug metabolism; however, on an effect been reported not to have carbamazepine kinetics [ = additive = additive sedative = additive = additive sedative = reduced drug = reduced drug = possible reduced = decreased side = decreased side = decreased side = reduced drug BI effects BI effects UC effects UC effects SI effectiveness BI effects UC effectiveness UC effectiveness OB drug effectiveness Schisandra chinensis Schisandra Hypericum perforatum Silybum marianum Silybum N-Acetylcysteine Piper methysticum Hypericum perforatum Piper methysticum Hypericum perforatum Ginkgo biloba Paracetamol Paracetamol Phenobarbitone and phenytoin Phenobarbitone Anticonvulsants Carbamazepine Anticonvulsants Anticonvulsants (general) 188 Herb and Nutrient-Drug Interaction Table ] 11 ] 12 ] 12 Recommendations Avoid concurrent use, unless Avoid under medical supervision. Potential for serotonin syndrome with concurrent use. Use such as extracts low-hyperforin Ze117 [ patient with concurrent Observe for use. Interaction risk is low at doses of standardized extracts [ 240 mg/day or lower Observe patient due to possible Observe state effects/hypomanic additive Avoid concurrent use, unless Avoid under medical supervision. Potential for serotonergic syndrome with concurrent use. such extract Use low-hyperforin as Ze117 [ Mechanism of interaction patient with Observe unknown. concurrent use ] 15 cant ] 8 ] 7 ] 11 ] 14 , ]. However, clinically signifi ]. However, 8 , 32 7 Case study (combination valerian and kava and kava Case study (combination valerian when preparation) increased lethargy [ combined with paroxetine A case report in a patient with Alzheimer’s A case report in a patient with Alzheimer’s disease suggested a possible increase in the receptors leading to function of GABA sedation with concurrent use of trazodone [ Due to the theories of serotonergic Due to the theories of serotonergic mechanism of action MI, caution should when using in conjunction be exercised wort. with antidepressants or St. John’s no reported cases of serotonin However, syndrome associated with MI to date [ interactions appear to be dose dependent [ Concurrent use may increase serotonin inhibition [ reuptake Induces CYP enzymes and P-glycoprotein. Pharmacokinetic trials and case studies reporting symptoms of serotonin syndrome [ rmed) = additive = additive effect = potential additive = potential additive = additive = additive effect = additive = additive effect UC BO effects OB (although effects unconfi SI SI inositol - Herb Potential interaction Evidence Piper methysticum Ginkgo biloba Myo Hypericum perforatum Hypericum perforatum Selective Selective serotonin inhibitors reuptake and serotonin norepinephrine inhibitors reuptake Drug class Antidepressants Atypical (bupropion) (continued) Herb and Nutrient-Drug Interaction Table 189 ] ] (continued) 11 11 cial interaction cial ] 12 patient and rmed. Observe patient and rmed. Observe Avoid concurrent use, unless Avoid under medical supervision. Potential for serotonergic syndrome with concurrent use. such extracts Use low-hyperforin as Ze117 [ Mechanism of interaction unconfi caution with concurrent exercise for use. Interaction risk is low at doses of standardized extracts [ 240 mg/day or lower Mechanism of interaction unconfi use caution with concurrent use. for Interaction risk is low at doses of standardized extracts [ 240 mg/day or lower Avoid concurrent use to ensure Avoid treatment effectiveness Possible benefi ] 8 ] extract) has extract) 16 ] ]. EGb 761 ]. One clinical trial ] 12 6 3 11 with cant side effects ] 6 Ginkgo biloba Case study reporting priapism, possibly due [ effects to vasodilation Clinical trial demonstrating increased with concurrent use and decreased effects [ side effects extrapyramidal reported no signifi concurrent treatment [ Based on pharmacological action, may have Based on pharmacological action, may have against drug- effect a hepatoprotective damage [ induced liver (standardized in not demonstrated interaction effects clinical trials [ May decrease plasma levels of tricyclics of tricyclics May decrease plasma levels and increase serotonin [ Pharmacokinetic trials demonstrating decreased blood concentration of with concurrent use [ fexofenadine = reduced drug = additive = additive effect = additive = additive effect and = reduced drug side = reduced drug OB OB reduced side effects BI effects SI effectiveness UC effectiveness Silybum marianum Silybum Hypericum perforatum Ginkgo biloba Ginkgo biloba Hypericum perforatum Ginkgo biloba Tricyclics Tricyclics Risperidone Antipsychotics Haloperidol Antihistamines Fexofenadine 190 Herb and Nutrient-Drug Interaction Table ] ] ] ] ] 7 7 7 7 11 ] 11 , 8 ] 11 , 8 Recommendations
Load more

Recommended publications
  • DHEA: Dehydroepiandrosterone
    DHEA: Dehydroepiandrosterone Joseph Pepping, Pharm.D. [Am J Health-Syst Pharm 57(22):2048-2056, 2000. © 2000 ASHP, Inc.] Introduction Dehydroepiandrosterone (DHEA) and its active metabolite, DHEA sulfate (DHEAS), are endogenous hormones synthesized and excreted primarily by the zona reticularis of the adrenal cortex in response to adrenocorticotropic hormone. The exact mechanism of action and clinical role, if any, of DHEA and DHEAS remain unclear. Epidemiological data indicate an inverse relationship between serum DHEA and DHEAS levels and the frequency of cancer, cardiovascular disease (in men only), Alzheimer's disease and other age-related disorders, immune function, and progression of HIV infection. [1] Animal (primarily rodent) studies have suggested many beneficial effects of DHEA, including improved immune function and memory and prevention of atherosclerosis, cancer, diabetes, and obesity. Many of the benefits seen in animal studies have yet to be shown in humans. [1-3] Uses Clinically substantiated (yet still controversial) uses of DHEA include replacement therapy in patients with low serum DHEA levels secondary to chronic disease, adrenal exhaustion, or corticosteroid therapy; treating systemic lupus erythematosus (SLE), improving bone density in postmenopausal women; improving symptoms of severe depression; improving depressed mood and fatigue in patients with HIV infection; and increasing the rate of reepithelialization in patients undergoing autologous skin grafting for burns. [1,4-8] Other possible uses (with some supporting clinical studies) include enhancing the immune response and sense of well-being in the elderly, decreasing certain cardiovascular risk factors, and treating male erectile dysfunction. [4,8-12] Use of DHEA to slow or reverse the aging process, improve cognitive function, promote weight loss, increase lean muscle mass, or slow the progression of Parkinson's disease and Alzheimer's disease is clinically unsubstantiated.
    [Show full text]
  • Exerts Anxiolytic-Like Effects Through GABAA Receptors in a Surgical Menopause Model in Rats
    Biomedicine & Pharmacotherapy 109 (2019) 2387–2395 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Original article Chrysin (5,7-dihydroxyflavone) exerts anxiolytic-like effects through GABAA receptors in a surgical menopause model in rats T ⁎ Juan Francisco Rodríguez-Landaa,b, , Fabiola Hernández-Lópezc, Jonathan Cueto-Escobedoa, Emma Virginia Herrera-Huertad, Eduardo Rivadeneyra-Domínguezb, Blandina Bernal-Moralesa,b, Elizabeth Romero-Avendañod a Laboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Veracruz, Mexico b Facultad de Química Farmacéutica Biológica, Universidad Veracruzana, Xalapa, Veracruz, Mexico c Hospital General de Zona con Medicina Familiar No. 28, Delegación Veracruz Norte, Instituto Mexicano del Seguro Social (H.G.Z. c/mf. No. 28, Delegación Veracruz Norte, IMSS), Martínez de la Torre, Veracruz, Mexico d Facultad de Ciencias Químicas, Universidad Veracruzana, Orizaba, Veracruz, Mexico ARTICLE INFO ABSTRACT Keywords: The present study investigated the effects of the flavonoid chrysin (5,7-dihydroxyflavone) on anxiety-like be- Anxiolytics havior in rats in a model of surgical menopause and evaluated the participation of γ-aminobutyric acid-A Chrysin (GABAA) receptors in these actions. At 12 weeks post-ovariectomy, the effects of different doses of chrysin (0.5, GABAA 1, 2, and 4 mg/kg) were evaluated in the elevated plus maze, light/dark test, and locomotor activity test, and Oophorectomy comparisons were made with the clinically effective anxiolytic diazepam. The participation of GABA receptors Ovariectomy A in the actions of chrysin was explored by pretreating the rats with the noncompetitive GABA chloride ion Surgical menopause A channel antagonist picrotoxin (1 mg/kg). The results showed that chrysin (2 and 4 mg/kg) reduced anxiety-like behavior in both the elevated plus maze and light/dark test, and these effects were similar to diazepam.
    [Show full text]
  • Abigail Marklew, Juha Kammonen, Emma Richardson & Jonathan
    Development and validation of NMDA receptor ligand- gated ion channel assays using the Qube 384 automated electrophysiology platform Abigail Marklew, Juha Kammonen, Emma Richardson & Jonathan Mann Saffron Walden, Essex, UK Abigail Marklew, Juha Kammonen, Emma Richardson and Gary Clark Saffron1 ABSTRACT Walden, Essex, UK 2 MATERIALS AND METHODS Ligand-gated ion channels are of particular interest to the pharmaceutical industry for the Cell Culture: HEK-NMDA NR1/N2A receptor cells were produced at Charles River Laboratories and treatment of diseases from a variety of therapeutic areas including CNS disorders, respiratory are commercially available. All cells were grown according to their respective SOPs as developed by disease and chronic pain. Ligand-gated ion channels have historically been investigated using Charles River, except for the use of D-(-)-AP-5 as antagonist during induction. Cells were kept in a fluorescence-based and low throughput patch-clamp techniques. However the development of the serum-free medium in the cell hotel on the Qube instrument for up to 4 hours during experiment. Qube 384 automated patch-clamp system has allowed rapid exchange of liquid and direct Induction: Cells were induced 24 h prior to use using 1 µg/mL tetracycline and 100 µM D-(-)-AP-5 in measurement of ion channel currents on a millisecond timescale, making it possible to run HTS neurobasal medium + 10% dialysed FBS. campaigns and support SAR with a functional readout. Solutions: The following extracellular saline solution was used (mM): 145 NaCl. 4 KCl, 10 HEPES, 10 Glucose, 2 CaCl2, pH7.4. Intracellular solution (mM): 70 KCl, 70 KF, 10 HEPES, 1 EGTA, pH7.2.
    [Show full text]
  • State of New York City's Plants 2018
    STATE OF NEW YORK CITY’S PLANTS 2018 Daniel Atha & Brian Boom © 2018 The New York Botanical Garden All rights reserved ISBN 978-0-89327-955-4 Center for Conservation Strategy The New York Botanical Garden 2900 Southern Boulevard Bronx, NY 10458 All photos NYBG staff Citation: Atha, D. and B. Boom. 2018. State of New York City’s Plants 2018. Center for Conservation Strategy. The New York Botanical Garden, Bronx, NY. 132 pp. STATE OF NEW YORK CITY’S PLANTS 2018 4 EXECUTIVE SUMMARY 6 INTRODUCTION 10 DOCUMENTING THE CITY’S PLANTS 10 The Flora of New York City 11 Rare Species 14 Focus on Specific Area 16 Botanical Spectacle: Summer Snow 18 CITIZEN SCIENCE 20 THREATS TO THE CITY’S PLANTS 24 NEW YORK STATE PROHIBITED AND REGULATED INVASIVE SPECIES FOUND IN NEW YORK CITY 26 LOOKING AHEAD 27 CONTRIBUTORS AND ACKNOWLEGMENTS 30 LITERATURE CITED 31 APPENDIX Checklist of the Spontaneous Vascular Plants of New York City 32 Ferns and Fern Allies 35 Gymnosperms 36 Nymphaeales and Magnoliids 37 Monocots 67 Dicots 3 EXECUTIVE SUMMARY This report, State of New York City’s Plants 2018, is the first rankings of rare, threatened, endangered, and extinct species of what is envisioned by the Center for Conservation Strategy known from New York City, and based on this compilation of The New York Botanical Garden as annual updates thirteen percent of the City’s flora is imperiled or extinct in New summarizing the status of the spontaneous plant species of the York City. five boroughs of New York City. This year’s report deals with the City’s vascular plants (ferns and fern allies, gymnosperms, We have begun the process of assessing conservation status and flowering plants), but in the future it is planned to phase in at the local level for all species.
    [Show full text]
  • 2020 Formulary: List of Covered Drugs
    Neighborhood INTEGRITY (Medicare-Medicaid Plan) 2020 Formulary: List of covered drugs PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN If you have questions, please call Neighborhood INTEGRITY at 1-844-812-6896, 8AM to 8PM, Monday – Friday; 8AM to 12PM on Saturday. On Saturday afternoons, Sundays and holidays, you may be asked to leave a message. Your call will be returned within the next business day. The call is free. TTY: 711. For more information, visit www.nhpri.org/INTEGRITY. HPMS Approved Formulary File Submission ID: H9576. We have made no changes to this formulary since 8/2019. H9576_PhmDrugListFinal2020 Populated Template 9/26/19 H9576_PhmDrugList20 Approved 8/5/19 Updated on 08/01/2019 Neighborhood INTEGRITY | 2020 List of Covered Drugs (Formulary) Introduction This document is called the List of Covered Drugs (also known as the Drug List). It tells you which prescription drugs and over-the-counter drugs are covered by Neighborhood INTEGRITY. The Drug List also tells you if there are any special rules or restrictions on any drugs covered by Neighborhood INTEGRITY. Key terms and their definitions appear in the last chapter of the Member Handbook. Table of Contents A. Disclaimers .............................................................................................................................. III B. Frequently Asked Questions (FAQ) ......................................................................................... IV B1. What prescription drugs are on the List of Covered Drugs?
    [Show full text]
  • Investigation Into Potential Endocrine Disruptive Effects of Sceletium Tortuosum
    Investigation into potential endocrine disruptive effects of Sceletium tortuosum by Letitia Louw Dissertation presented for the degree of Master of Science in the Faculty of Science at Stellenbosch University Supervisor: Prof C. Smith Co-supervisor: Prof AC. Swart March 2018 Stellenbosch University https://scholar.sun.ac.za Declaration By submitting this dissertation electronically, I declare that the entirety of the work contained therein is my own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch University will not infringe any third party rights and that I have not previously in its entirety or in part submitted it for obtaining any qualification. March 2018 Copyright © 2018 Stellenbosch University All rights reserved i Stellenbosch University https://scholar.sun.ac.za What if I fall? Oh, but darling what if you fly? ii Stellenbosch University https://scholar.sun.ac.za ABSTRACT Depression has been recognised by the World Health Organisation (WHO) as the leading cause of disability, affecting an estimated 300 million people globally. To date antidepressants are prescribed as the first step in the treatment strategy. However, finding the appropriate antidepressant is often a lengthy process and is usually accompanied by side effects. A major and often unexpected side effect is reduced sexual function, which has been reported to aggravate depression and could possibly lead to poor compliance to medication. Sceletium tortuosum is a native South African plant, which has exhibited both antidepressant and anxiolytic properties. Although the exact mechanism of action remains to be elucidated, there are currently two hypotheses which attempt to explain it’s mechanism of action.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • DHEA) and Androstenedione Has Minimal Effect on Immune Function in Middle-Aged Men
    Original Research Ingestion of a Dietary Supplement Containing Dehydroepiandrosterone (DHEA) and Androstenedione Has Minimal Effect on Immune Function in Middle-Aged Men Marian L. Kohut, PhD, James R. Thompson, MS, Jeff Campbell, BA, Greg A. Brown, MS, Matthew D. Vukovich, PhD, Dave A. Jackson, MS, Doug S. King, PhD Department of Health and Human Performance, Iowa State University, Ames, Iowa Key words: aging, cytokines, lymphocyte, hormones, androstenedione, DHEA Objective: This study investigated the effects of four weeks of intake of a supplement containing dehydro- epiandrosterone (DHEA), androstenedione and herbal extracts on immune function in middle-aged men. Design: Subjects consumed either an oral placebo or an oral supplement for four weeks. The supplement contained a total daily dose of 150 mg DHEA, 300 mg androstenedione, 750 mg Tribulus terrestris, 625 mg chrysin, 300 mg indole-3-carbinol and 540 mg saw palmetto. Measurements: Peripheral blood mononuclear cells were used to assess phytohemagglutinin(PHA)-induced lymphocyte proliferation and cytokine production. The cytokines measured were interleukin (IL)-2, IL-4, IL-10, IL-1␤, and interferon (IFN)-␥. Serum free testosterone, androstenedione, estradiol, dihydrotestosterone (DHT) were also measured. Results: The supplement significantly increased serum levels of androstenedione, free testosterone, estradiol and DHT during week 1 to week 4. Supplement intake did not affect LPS or ConA proliferation and had minimal effect on PHA-induced proliferation. LPS-induced production of IL-1beta, and PHA-induced IL-2, IL-4, IL-10, or IFN-gamma production was not altered by the supplement. The addition of the same supplement, DHEA or androstenedione alone to lymphocyte cultures in vitro did not alter lymphocyte proliferation, IL-2, IL-10, or IFN-␥, but did increase IL-4.
    [Show full text]
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • Cordyceps Medicinal Fungus: Harvest and Use in Tibet
    HerbalGram 83 • August – October 2009 83 • August HerbalGram Kew’s 250th Anniversary • Reviving Graeco-Arabic Medicine • St. John’s Wort and Birth Control The Journal of the American Botanical Council Number 83 | August – October 2009 Kew’s 250th Anniversary • Reviving Graeco-Arabic Medicine • Lemongrass for Oral Thrush • Hibiscus for Blood Pressure • St. John’s Wort and BirthWort Control • St. John’s Blood Pressure • HibiscusThrush for Oral for 250th Anniversary Medicine • Reviving Graeco-Arabic • Lemongrass Kew’s US/CAN $6.95 Cordyceps Medicinal Fungus: www.herbalgram.org Harvest and Use in Tibet www.herbalgram.org www.herbalgram.org 2009 HerbalGram 83 | 1 STILL HERBAL AFTER ALL THESE YEARS Celebrating 30 Years of Supporting America’s Health The year 2009 marks Herb Pharm’s 30th anniversary as a leading producer and distributor of therapeutic herbal extracts. During this time we have continually emphasized the importance of using the best quality certified organically cultivated and sustainably-wildcrafted herbs to produce our herbal healthcare products. This is why we created the “Pharm Farm” – our certified organic herb farm, and the “Plant Plant” – our modern, FDA-audited production facility. It is here that we integrate the centuries-old, time-proven knowledge and wisdom of traditional herbal medicine with the herbal sciences and technology of the 21st Century. Equally important, Herb Pharm has taken a leadership role in social and environmental responsibility through projects like our use of the Blue Sky renewable energy program, our farm’s streams and Supporting America’s Health creeks conservation program, and the Botanical Sanctuary program Since 1979 whereby we research and develop practical methods for the conser- vation and organic cultivation of endangered wild medicinal herbs.
    [Show full text]
  • In Vivo Effect of PC-SPES on Prostate Growth and Hepatic CYP3A Expression in Rats
    JPET Fast Forward. Published on April 3, 2003 as DOI: 10.1124/jpet.102.048645 JPETThis Fast article Forward. has not been Published copyedited and on formatted. April 3, The 2003 final asversion DOI:10.1124/jpet.102.048645 may differ from this version. JPET #48645 In Vivo Effect of PC-SPES on Prostate Growth and Hepatic CYP3A Expression in Rats Teri Wadsworth, Hataya Poonyagariyagorn, Elinore Sullivan, Dennis Koop and Charles E. Roselli. Downloaded from Department of Physiology and Pharmacology Oregon Health & Science University, Portland, OR. jpet.aspetjournals.org at ASPET Journals on September 26, 2021 1 Copyright 2003 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on April 3, 2003 as DOI: 10.1124/jpet.102.048645 This article has not been copyedited and formatted. The final version may differ from this version. JPET #48645 Running Title: In vivo effects of PC-SPES Correspondence: Dr. Charles E. Roselli, Department of Physiology and Pharmacology L334, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97201-3098, Tel (503) 494-5837, FAX (503) 494-4352, email: [email protected] Number of text pages: 20 number of tables: 4 Downloaded from number of figures: 4 number of references: 40 jpet.aspetjournals.org number of words in the Abstract: 250 number of words the Introduction: 748 number of words in the Discussion: 1478 at ASPET Journals on September 26, 2021 nonstandard abbreviations: National Institute of Diabetes and Digestive and Kidney Disease (NIDDK);
    [Show full text]
  • Part X. Uniform Controlled Dangerous Substances Law §961. Definitions
    Part X. Uniform Controlled Dangerous Substances Law [Editor’s Note: The Uniform Controlled Dangerous Substances Law was created by Act 634 of 1972 Legislature. Subsequent amendments are noted herein.] §961. Definitions As used in this Part, the following terms shall have the meaning ascribed to them in this Section unless the context clearly indicates otherwise: (1) “Addict” means a drug dependent person who habitually uses any narcotic drugs as to have lost the power of self-control with reference to his use of said drugs. (2) “Administer” means to deliver under the auspices of a registered practitioner a controlled dangerous substance to the ultimate user or human research subject by injection, or for inhalation, or ingestion, or by any other means except where otherwise provided by law. (3) “Agent” means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser, but does not include a common or contract carrier, public warehouseman, or employee thereof. (4) “Aggregate” means the gross weight of an exhibit of evidence. (Added by Act 677 of 2018 Legislature, effective August 1, 2018) (5) “Apothecary” means a licensed pharmacist as defined by the laws of this state, and where the context so requires, the owner of the store or other place of business where narcotic drugs are compounded or dispensed by a licensed pharmacist; but nothing in this Part shall be construed as conferring on a person who is not registered nor licensed as a pharmacist any authority, right, or privilege that is not granted to him by the pharmacy laws of this state.
    [Show full text]